Breast Cancer Research and Treatment

, Volume 127, Issue 1, pp 129–131 | Cite as

Neoadjuvant chemotherapy for breast cancer: a surgeon’s checklist

Invited Commentary


Breast Conservation Postmastectomy Radiotherapy Post Mastectomy Radiotherapy Hormone Responsive Breast Cancer Axillary Nodal Staging 


  1. 1.
    Goldhirsch A, Wood WC, Gelber RD et al (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365PubMedCrossRefGoogle Scholar
  2. 2.
    Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRefGoogle Scholar
  3. 3.
    Kaufmann M, Hortobagyi GN, Goldhirsch A et al (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940–1949PubMedCrossRefGoogle Scholar
  4. 4.
    Smith IE, Dowsett M, Ebbs SR et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108–5116PubMedCrossRefGoogle Scholar
  5. 5.
    Buchholz TA, Lehman CD, Harris JR et al (2008) Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol 26:791–797PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  1. 1.University of MichiganAnn ArborUSA

Personalised recommendations